Ident. | Authors (with country if any) | Title |
---|
000107 (2011) |
Karl Kieburtz [États-Unis] | Twice‐daily, low‐dose pramipexole in early Parkinson's disease: A randomized, placebo‐controlled trial |
000113 (2011) |
István Sziklai [Hongrie] ; Judit Szilvássy [Hongrie] ; Zoltán Szilvássy [Hongrie] | Tinnitus control by dopamine agonist pramipexole in presbycusis patients: A randomized, placebo‐controlled, double‐blind study |
000127 (2011) |
Hasmet A. Hanagasi [Turquie] ; Hakan Gurvit [Turquie] ; P Nar Unsalan [Turquie] ; Hilal Horozoglu [Turquie] ; Nese Tuncer [Turquie] ; Aynur Feyzioglu [Turquie] ; Dilek Ince Gunal [Turquie] ; Gorsev G. Yener [Turquie] ; Raif Cakmur [Turquie] ; Huseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study |
000164 (2011) |
Claudia Trenkwalder [Allemagne] ; Bryan Kies [Afrique du Sud] ; Monika Rudzinska [Pologne] ; Jennifer Fine [Afrique du Sud] ; Janos Nikl [Hongrie] ; Krystyna Honczarenko [Pologne] ; Peter Dioszeghy [Hongrie] ; Dennis Hill [États-Unis] ; Tim Anderson [Nouvelle-Zélande] ; Vilho Myllyla [Finlande] ; Jan Kassubek [Allemagne] ; Malcolm Steiger [Royaume-Uni] ; Marco Zucconi [Italie] ; Eduardo Tolosa [Espagne] ; Werner Poewe [Autriche] ; Erwin Surmann [Allemagne] ; John Whitesides [États-Unis] ; Babak Boroojerdi [Allemagne] ; Kallol Ray Chaudhuri [Royaume-Uni] ; the RECOVER Study Group | Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER) |
000271 (2011) |
Helge Hellriegel [Allemagne] ; Jan Raethjen [Allemagne] ; G. Deuschl [Allemagne] ; Jens Volkmann [Allemagne] | Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study |
000411 (2011) |
Kitty K. Wong [Australie] ; Jane E. Alty [Australie] ; Amanda G. Goy [Australie] ; Sanjay Raghav [Australie] ; David C. Reutens [Australie] ; Peter A. Kempster [Australie] | A randomized, double‐blind, placebo‐controlled trial of levetiracetam for dyskinesia in Parkinson's disease |
000520 (2010) |
Endre Pal [Hongrie] ; Ferenc Nagy [Hongrie] ; Zsuzsanna Aschermann [Hongrie] ; Eva Balazs [Hongrie] ; Norbert Kovacs [Hongrie] | The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double‐blind, placebo‐controlled study |
000549 (2010) |
Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne] | Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study |
000611 (2010) |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
000841 (2010) |
Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande] | A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease |
000D08 (2008) |
Christopher G. Goetz [États-Unis] ; Joanne Wuu [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Charles H. Adler [États-Unis] ; Stanley Fahn [États-Unis] ; Curt R. Freed [États-Unis] ; Robert A. Hauser [États-Unis] ; Warren C. Olanow [États-Unis] ; Ira Shoulson [États-Unis] ; P. K. Tandon [États-Unis] ; Sue Leurgans [États-Unis] | Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions |
000E38 (2008) |
David Devos [France] ; Kathy Dujardin [France] ; Isabelle Poirot [France] ; Caroline Moreau [France] ; Olivier Cottencin [France] ; Pierre Thomas [France] ; Alain Destée [France] ; Regis Bordet [France] ; Luc Defebvre [France] | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study |
000E78 (2008) |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
000F39 (2007) |
Tanya Gurevich [Israël] ; Chava Peretz [Israël] ; Orna Moore [Israël] ; Nina Weizmann [Israël] ; Nir Giladi [Israël] | The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study |
000F47 (2007) |
Paolo Barone [Italie] ; Janice Lamb [Royaume-Uni] ; Amanda Ellis [Royaume-Uni] ; Zoe Clarke [Royaume-Uni] | Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease |
000F60 (2007) |
Nir Giladi [Israël] ; Babak Boroojerdi [Allemagne] ; Amos D. Korczyn [Israël] ; David J. Burn [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] | Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole |
001018 (2007) |
Roberta Zangaglia [Italie] ; Emilia Martignoni [Italie] ; Margaret Glorioso [Italie] ; Maria Ossola [Italie] ; Giulio Riboldazzi [Italie] ; Daniela Calandrella [Italie] ; Gabriele Brunetti [Italie] ; Claudio Pacchetti [Italie] | Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study |
001132 (2007) |
Theresa A. Zesiewicz [États-Unis] ; Christopher L. Ward [États-Unis] ; Robert A. Hauser [États-Unis] ; Jason L. Salemi [États-Unis] ; Shaila Siraj [États-Unis] ; Maria-Carmen Wilson [États-Unis] ; Kelly L. Sullivan [États-Unis] | A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremor |
001139 (2007) |
Theresa A. Zesiewicz [États-Unis] ; Christopher L. Ward [États-Unis] ; Robert A. Hauser [États-Unis] ; Juan Sanchez-Ramos [États-Unis] ; Joseph F. Staffetti [États-Unis] ; Kelly L. Sullivan [États-Unis] | A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor |
001140 (2007) |
Carlos Singer [États-Unis] ; Janice Lamb [Royaume-Uni] ; Amanda Ellis [Royaume-Uni] ; Gary Layton [Royaume-Uni] | A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease |
001301 (2006) |
Rodrigo Mercado [Canada] ; Constantine Constantoyannis [Canada] ; Tomasz Mandat [Canada] ; Ajit Kumar [Canada] ; Michael Schulzer [Canada] ; A. Jon Stoessl [Canada] ; Christopher R. Honey [Canada] | Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation |